LABORATORY CORPORATION OF AMERICA HOLDINGS

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 201 of H.R. 7623, the Telehealth Modernization Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development;

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Section 201 of H.R. 7024, the Tax Relief for American Families and Workers Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.